試す 金 - 無料
"The pharma packaging landscape is evolving rapidly, driven by advancements in technology and changing regulatory landscapes"
Bio Spectrum
|BioSpectrum India Jan 2025
Recently elevated from CEO to Chairman and Managing Director (CMD) of Ecobliss India, AVPS Chakravarthi, has been at the forefront of developing eco-friendly packaging technologies, particularly for the pharma, biotechnology and allied industries, worldwide.
-

Chakravarthi, with over two decades of experience, has turned Ecobliss India into a pioneer in the field of blister packaging, catering to industries such as pharmaceuticals, food, and FMCG. Apart from his corporate endeavours, he serves as a global ambassador for the World Packaging Organization (WPO), promoting best practices in packaging to reduce environmental impact. He has also been recognised with numerous awards for his contributions to the industry, including honours for innovation and leadership in sustainable packaging. In an interview with BioSpectrum, Chakravarthi shares his perspective and insights into the new and emerging trends in pharmaceutical packaging and the future ahead. Edited excerpts:
Could you tell us about your journey from being the CEO and presently to CMD of Ecobliss India?
The transition to CMD is not a significant milestone as it is business as usual. However, personally, it is a moment of pride, reflecting the trust and faith my team and stakeholders have in me. It allows me to focus on strategic growth, mentorship, and steering Ecobliss India toward greater innovation and sustainability. I believe this position enables me to amplify the company’s vision and legacy in the pharmaceutical packaging sector.
In this role, I see myself as more of a mentor and guide. It’s about empowering my team, encouraging fresh ideas, and ensuring that Ecobliss remains a leader in the pharmaceutical packaging industry. Sustainability and innovation are close to my heart, and this position enables me to champion these values more effectively, aligning the company’s goals with global demands for eco-friendly solutions.
What are your immediate priorities and longterm strategies for steering Ecobliss India’s growth, especially in the pharmaceutical packaging domain?
このストーリーは、Bio Spectrum の BioSpectrum India Jan 2025 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、10,000 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
Bio Spectrum からのその他のストーリー

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size